Evidence map›Paper›PMID 31739735›Full record

ArticleBioengineered2019

Construction of Epstein-Bar virus cocktail peptide fused with Fcγ of IgG: as a potential delivery system for vaccine development.

Saeid Amel Jamehdar, Samira Tabaei, Baratali Mashkani, Reza Karimi, Morteza Motallebnezhad, Arezoo Esmaili

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saeid Amel JamehdarAntimicrobial Resistance Research Center, Mashhad University of Medical Science, Mashhad, Iran.
Samira TabaeiDepartment of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Baratali MashkaniDepartment of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Reza KarimiDepartment of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.
Morteza MotallebnezhadImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Arezoo EsmailiDepartment of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV) associated with several diseases such as contagious mononucleosis chronic active EBV infection, and diverse sorts of malignant tumors. Therefore, using applicable vaccines could be advantageous for public health. Yet, the vaccine has been unavailable to protect from EBV so far. In the current study, to develop a multi-peptide vaccine for EBV and assess its expression in

Indexed as

Amino Acid SequenceBurkitt LymphomaCloning, MolecularGene ExpressionGenetic VectorsHerpesvirus 4, HumanHumansImmunoglobulin Fc FragmentsInfectious MononucleosisMembrane GlycoproteinsPeptidesPichiaRecombinant Fusion ProteinsVaccines, SubunitViral Envelope ProteinsViral Matrix ProteinsEBV-associated membrane antigen, Epstein-Barr virusglycoprotein 85, Epstein-Barr virusGP 300-350, Epstein-Barr virusImmunoglobulin Fc FragmentsMembrane GlycoproteinsPeptidesRecombinant Fusion ProteinsVaccines, SubunitViral Envelope ProteinsViral Matrix ProteinsViral VaccinesEpstein-Bar virusfusion peptidepeptide vaccinePichia pastoris

Identifiers

PMID31739735
PMCPMC8530268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.